New Lipid-Lowering Targets Beyond Statins Reshape Cardiovascular Risk Management
A 2025 review maps the expanding arsenal of lipid-lowering therapies targeting LDL-C, triglycerides, apoB, and Lp(a) to tackle residual cardiovascular risk.
Summary
Cardiovascular disease driven by dyslipidaemia remains a leading global killer, and statins alone no longer tell the whole story. This comprehensive 2025 review from the European Heart Journal charts the evolving landscape of lipid-lowering targets — from well-established HMG-CoA reductase inhibition to newer agents blocking PCSK9, ANGPTL3, apoC-III, and CETP. Emerging strategies targeting lipoprotein(a) via antisense therapies show particular promise for patients with residual cardiovascular risk. Together, these advances offer clinicians a growing toolkit for individuals who are statin-intolerant, have specific lipid abnormalities, or remain at high risk despite current treatment.
Detailed Summary
Cardiovascular disease remains one of the most pressing global health challenges, and abnormal lipid profiles — particularly elevated LDL cholesterol — are among its most modifiable drivers. Yet even optimally treated patients often retain substantial residual risk, pointing to lipid fractions beyond LDL-C as important targets. This 2025 review in the European Heart Journal by Ballantyne and Norata synthesizes the molecular mechanisms and translational significance of both established and emerging lipid-lowering strategies.
Statins remain the cornerstone of therapy, inhibiting HMG-CoA reductase to suppress cholesterol biosynthesis and upregulate hepatic LDL receptors. Bempedoic acid offers a statin-adjacent alternative by targeting ATP citrate lyase — one step upstream in the mevalonate pathway — with a liver-selective profile that sidesteps muscle-related side effects common with statins.
PCSK9 inhibitors represent the most significant advance of the past decade. By preventing LDL receptor degradation, agents including evolocumab, alirocumab, inclisiran, lerodalcibep, and the oral candidate MK0616 (enlicitide decanoate) can dramatically lower LDL-C. Ezetimibe continues to serve as a complementary agent by blocking intestinal cholesterol absorption.
Beyond LDL-C, the review highlights ANGPTL3 inhibition — which lowers both triglycerides and LDL-C independent of LDL receptors — and apoC-III inhibition, which liberates lipoprotein lipase activity to clear triglyceride-rich particles even in patients with complete LPL deficiency. CETP inhibition also accelerates catabolism of apoB-containing lipoproteins. Antisense and RNA-based strategies targeting lipoprotein(a) are advancing through trials and may soon provide a direct intervention against this genetically determined, cardiovascular risk factor.
The review underscores that the field is rapidly maturing, offering tailored options for patients resistant to existing therapies or with distinct lipid phenotypes. Ongoing cardiovascular outcomes trials will ultimately determine the clinical impact of many of these newer agents.
Key Findings
- PCSK9 inhibitors including novel oral agent MK0616 prevent LDL receptor degradation and substantially reduce LDL-C.
- ANGPTL3 inhibition lowers both triglycerides and LDL-C independently of LDL receptor status.
- ApoC-III inhibition restores lipoprotein lipase activity to clear triglycerides, even in complete LPL deficiency.
- Antisense therapies targeting Lp(a) are emerging as promising strategies for a previously untreatable cardiovascular risk factor.
- Bempedoic acid offers a liver-selective statin alternative by inhibiting ATP citrate lyase upstream of HMG-CoA reductase.
Methodology
This is a narrative review article published in the European Heart Journal, synthesizing current molecular mechanisms and clinical evidence across multiple lipid-lowering drug classes. As a review, it does not report original experimental or clinical trial data. Conclusions are drawn from the existing literature as interpreted by the authors.
Study Limitations
As a review based solely on the abstract, the full breadth of evidence discussed, including specific trial data and patient population details, cannot be fully assessed. The review likely reflects the authors' synthesis and may carry selection bias in which studies and mechanisms are emphasized. Many highlighted emerging therapies are still in trials, and long-term cardiovascular outcomes evidence remains incomplete for several agents.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.